Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04530565 · ClinicalTrials.gov registry record · Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

A Phase 3 study of B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 3
Development phase
348
Enrollment target
20
Study locations

NCT04530565 is a Phase 3 study of B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 348 participants, above the 128-participant average among 8 other B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials with a reported enrollment target (172% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04530565, a Phase 3 study of B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 3
Development phase
348 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

Conditions Studied

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions

  • DRUG Cyclophosphamide
  • PROCEDURE Biospecimen Collection
  • DRUG Cytarabine
  • BIOLOGICAL Blinatumomab
  • PROCEDURE Bone Marrow Aspiration and Biopsy

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage

California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
  • Community Cancer Institute - Clovis
  • University Oncology Associates - Clovis
  • City of Hope Comprehensive Cancer Center - Duarte
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • UC San Diego Moores Cancer Center - La Jolla
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith

Connecticut

  • Yale University - New Haven

Georgia

  • Augusta University Medical Center - Augusta

Hawaii

  • Hawaii Cancer Care Inc - Waterfront Plaza - Honolulu

Trial Details

FieldValue
Enrollment Target 348 participants
Start Date 2021-01-25
Est. Completion 2028-07-01
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04530565

The ClinicalTrials.gov registry entry for NCT04530565 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 8 other B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 trials with a reported enrollment target (172% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT04530565 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Alaska, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT04530565 about?

NCT04530565 is a clinical study titled "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults". This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The in...

What is the current status of trial NCT04530565?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2021-01-25. Estimated completion is 2028-07-01.

What conditions does trial NCT04530565 study?

This clinical trial studies the following conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1.

What interventions are being tested in trial NCT04530565?

The interventions under investigation include: Cyclophosphamide (DRUG), Biospecimen Collection (PROCEDURE), Cytarabine (DRUG), Blinatumomab (BIOLOGICAL), Bone Marrow Aspiration and Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT04530565?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04530565 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.